Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Gonadal and Placental Hormones01:24

Gonadal and Placental Hormones

The gonads, namely the testes in males and the ovaries in females, are pivotal in producing gonadal hormones that orchestrate the intricate processes of sexual development and reproduction.
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hnrnpa1 is essential for early zebrafish development and lipid metabolism: insights from a novel zebrafish knockout model.

Frontiers in cell and developmental biology·2026
Same author

Acylcarnitines and prediction of renal function decline in type 2 diabetes.

BMJ open diabetes research & care·2026
Same author

Optimization of a targeted metabolomics kit for dried blood spots analysis and longitudinal comparison with serum.

Metabolomics : Official journal of the Metabolomic Society·2026
Same author

Txnrd2 loss in skeletal muscle causes muscle atrophy and drives leanness and obesity resistance.

Redox biology·2026
Same author

Urea cycle modulation by combined SGLT2 inhibitors and metformin.

BMC medicine·2026
Same author

Integrative Metabolomics of Targeted and Nontargeted Analyses in T2D Progression.

Diabetes care·2025

Related Experiment Video

Updated: Jun 23, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

Recent advances in 17beta-hydroxysteroid dehydrogenases.

Cornelia Prehn1, Gabriele Möller, Jerzy Adamski

  • 1Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Experimental Genetics, Genome Analysis Center, Neuherberg, Germany.

The Journal of Steroid Biochemistry and Molecular Biology
|May 16, 2009
PubMed
Summary

17beta-hydroxysteroid dehydrogenases (17beta-HSDs) are crucial for steroid metabolism and linked to diseases like cancer. Understanding their roles and using metabolomics can aid in developing new drugs targeting these enzymes.

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Related Experiment Videos

Last Updated: Jun 23, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Area of Science:

  • Biochemistry
  • Endocrinology
  • Pharmacology

Background:

  • 17beta-hydroxysteroid dehydrogenases (17beta-HSDs) are key enzymes catalyzing steroid metabolism at position 17.
  • Dysfunctions in 17beta-HSDs are implicated in various human diseases, including breast cancer, prostate cancer, endometriosis, metabolic syndrome, and mental disorders.
  • These enzymes represent significant drug targets due to their association with disease pathology.

Purpose of the Study:

  • To review the identities and functions of 17beta-HSDs.
  • To highlight recent advancements in understanding their physiological roles in steroid and lipid metabolism.
  • To explore the potential of metabolomics in drug development targeting 17beta-HSDs.

Main Methods:

  • Literature review of scientific publications on 17beta-HSDs.
  • Analysis of studies detailing enzyme function and disease associations.
  • Exploration of metabolomic approaches for drug discovery.

Main Results:

  • Detailed identities and classifications of various 17beta-HSDs.
  • Elucidation of the physiological roles of 17beta-HSDs in complex metabolic pathways.
  • Demonstration of the utility of metabolomics in identifying and validating drug targets.

Conclusions:

  • 17beta-HSDs are critical regulators of steroid and lipid metabolism with profound physiological and pathological implications.
  • Targeting 17beta-HSDs offers a promising therapeutic strategy for a range of diseases.
  • Metabolomics provides powerful tools for advancing drug development in this area.